Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Melanoma/CSPG4-Enhanced Collagen-Mediated Contact Guidance Requires Mutant Active BRAF and the CSPG4 Core Protein Cytoplasmic Domain.

Cellular and molecular bioengineering·2026
Same author

Social determinants are associated with clinical presentation of acute pathological fracture in metastatic long-bone disease.

Journal of bone oncology·2025
Same author

External validation of 12 existing survival prediction models for patients with spinal metastases.

The spine journal : official journal of the North American Spine Society·2025
Same author

External validation of the SORG machine learning for 90-day and 1-year mortality in patients suffering from extremity metastatic disease in an European cohort of 174 patients.

Acta orthopaedica Belgica·2025
Same author

Development of Machine Learning Algorithms for Identifying Patients With Limited Health Literacy.

Journal of evaluation in clinical practice·2024
Same author

Analysis of complications and revisions after spine surgery in 270 multiple myeloma patients with spinal involvement.

European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·2023

Related Experiment Video

Updated: Jun 13, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

CSPG4 in cancer: multiple roles.

X Wang1, Y Wang, L Yu

  • 1University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15232, USA.

Current Molecular Medicine
|May 12, 2010
PubMed
Summary

Chondroitin sulfate proteoglycan 4 (CSPG4) is found on various cancer cells and promotes tumor growth. CSPG4-specific antibodies effectively inhibit cancer progression and metastasis, offering a new immunotherapy target.

More Related Videos

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase
09:51

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase

Published on: June 30, 2023

Related Experiment Videos

Last Updated: Jun 13, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase
09:51

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase

Published on: June 30, 2023

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Chondroitin sulfate proteoglycan 4 (CSPG4), also known as High Molecular Weight-Melanoma Associated Antigen, is a cell surface proteoglycan.
  • CSPG4 is expressed in melanoma, various carcinomas, and sarcomas, including cancer stem cells in specific head and neck and breast cancers.

Purpose of the Study:

  • To investigate the role of CSPG4 in tumor growth and survival.
  • To evaluate the therapeutic potential of CSPG4-specific monoclonal antibodies (mAb) in cancer treatment.

Main Methods:

  • In vitro studies assessing the effect of CSPG4-specific mAb on tumor cell properties.
  • In vivo studies evaluating the efficacy of CSPG4-specific mAb in inhibiting tumor growth and metastasis.

Main Results:

  • CSPG4 expression is linked to tumor cell growth and survival.
  • CSPG4-specific mAb inhibit tumor cell growth, migration, and survival signaling pathways in vitro.
  • CSPG4-specific mAb demonstrate efficacy in inhibiting tumor growth and metastasis in vivo.

Conclusions:

  • CSPG4 plays a critical role in the progression of various cancers.
  • CSPG4 represents a promising therapeutic target for developing novel mAb-based immunotherapies against cancer.